The prognostic utility of IGF-1 in hepatocellular carcinoma treated with stereotactic body radiotherapy.

ABSTRACT:

Background

Hepatocellular carcinoma (HCC) poses a significant challenge for patients ineligible for surgical resection or liver transplantation. Local therapies like Stereotactic Body Radiotherapy (SBRT) are crucial for those with liver-limited disease. Insulin-like growth factor-1 (IGF-1) is a potential biomarker for liver function. This study evaluates IGF-1's prognostic value in predicting survival outcomes in HCC patients undergoing SBRT.

Methods

We analyzed 42 HCC patients treated with SBRT between May 2021 and January 2024, with IGF-1 levels measured within four weeks before SBRT. Patient demographics, tumor metrics, and clinical outcomes were examined. The prognostic significance of IGF-1 was assessed using Cox proportional hazards and ROC curve analysis to determine

SUBMITTER: Mohamed AA 

PROVIDER: S-EPMC11609351 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature